James DArecca Insider Trading $AGN Allergan plc
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for James DArecca.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of James DArecca. James DArecca is Chief Financial Officer in TherapeuticsMD, Inc. ($TXMD) and CHIEF ACCOUNTING OFFICER in Allergan plc ($AGN) and SVP Chief Accounting Officer in Allergan plc ($AGN).
James DArecca in Allergan plc
Trading Symbol: AGNIndustry: PHARMACEUTICAL PREPARATIONS [2834]
Position of James DArecca: SVP Chief Accounting Officer, CHIEF ACCOUNTING OFFICER
Holdings: 0 shares
Current Value: $0
Latest Transaction: May 11 2020
$AGN Market Capitalization: $87.25B
$AGN Previous Close: $234.43
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of James DArecca in Allergan plc
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Option Exercise | D | 0.00 | 3,534 | 0 | 0 | |
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Option Exercise | D | 0.00 | 3,534 | 0 | 0 | |
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Option Exercise | D | 224.00 | 4,957 | 1,110,368 | 0 | |
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Option Exercise | D | 224.00 | 4,957 | 1,110,368 | 0 | |
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Option Exercise | D | 296.14 | 1,169 | 346,188 | 0 | |
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Option Exercise | D | 296.14 | 1,169 | 346,188 | 0 | |
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Sell | D | 0.00 | 6,324 | 0 | 0 | 6.3 K to 0 (-100.00 %) |
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Sell | D | 0.00 | 6,324 | 0 | 0 | 6.3 K to 0 (-100.00 %) |
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Sell | D | 0.00 | 3,511 | 0 | 0 | 3.5 K to 0 (-100.00 %) |
May 11 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Sell | D | 0.00 | 3,511 | 0 | 0 | 3.5 K to 0 (-100.00 %) |
Mar 10 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 191.95 | 718 | 137,820 | 9,834 | 10.6 K to 9.8 K (-6.80 %) |
Mar 04 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Grant | A | 193.84 | 3,611 | 699,956 | 10,552 | 6.9 K to 10.6 K (+52.02 %) |
Jan 02 2020 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 191.17 | 92 | 17,588 | 6,941 | 7 K to 6.9 K (-1.31 %) |
Mar 11 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 145.06 | 113 | 16,392 | 7,033 | 7.1 K to 7 K (-1.58 %) |
Mar 11 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 143.00 | 359 | 51,337 | 7,146 | 7.5 K to 7.1 K (-4.78 %) |
Mar 08 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Grant | A | 137.51 | 2,036 | 279,970 | 7,505 | 5.5 K to 7.5 K (+37.23 %) |
Mar 06 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 139.12 | 114 | 15,860 | 5,469 | 5.6 K to 5.5 K (-2.04 %) |
Jan 03 2019 | AGN | Allergan plc | DArecca James | SVP Chief Accountin ... | Payment of Exercise | F | 133.66 | 147 | 19,648 | 5,453 | 5.6 K to 5.5 K (-2.62 %) |
Mar 09 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Payment of Exercise | F | 153.50 | 79 | 12,127 | 5,600 | 5.7 K to 5.6 K (-1.39 %) |
Mar 08 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Grant | A | 153.22 | 1,696 | 259,861 | 5,679 | 4 K to 5.7 K (+42.58 %) |
Mar 08 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Payment of Exercise | F | 153.22 | 93 | 14,249 | 3,983 | 4.1 K to 4 K (-2.28 %) |
Mar 06 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Payment of Exercise | F | 148.73 | 70 | 10,411 | 4,076 | 4.1 K to 4.1 K (-1.69 %) |
Mar 06 2018 | AGN | Allergan plc | DArecca James | Chief Accounting Of ... | Payment of Exercise | F | 144.02 | 76 | 10,946 | 4,146 | 4.2 K to 4.1 K (-1.80 %) |
Jan 02 2018 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Payment of Exercise | F | 163.58 | 100 | 16,358 | 4,222 | 4.3 K to 4.2 K (-2.31 %) |
Oct 30 2017 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Option Exercise | M | 0.00 | 799 | 0 | 0 | |
Oct 30 2017 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Buy | M | 0.00 | 799 | 0 | 4,322 | 3.5 K to 4.3 K (+22.68 %) |
Mar 09 2017 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Payment of Exercise | F | 239.44 | 77 | 18,437 | 3,523 | 3.6 K to 3.5 K (-2.14 %) |
Mar 09 2017 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Grant | A | 239.60 | 1,085 | 259,966 | 3,600 | 2.5 K to 3.6 K (+43.14 %) |
Mar 07 2017 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Payment of Exercise | F | 245.63 | 66 | 16,212 | 2,515 | 2.6 K to 2.5 K (-2.56 %) |
Mar 07 2017 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Payment of Exercise | F | 245.63 | 72 | 17,685 | 2,581 | 2.7 K to 2.6 K (-2.71 %) |
Feb 03 2017 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Option Exercise | C | 229.32 | 238 | 54,578 | 0 | |
Feb 03 2017 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Payment of Exercise | F | 229.32 | 92 | 21,097 | 2,653 | 2.7 K to 2.7 K (-3.35 %) |
Feb 03 2017 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Grant | A | 229.32 | 238 | 54,578 | 2,745 | 2.5 K to 2.7 K (+9.49 %) |
May 12 2016 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Grant | A | 284.43 | 914 | 259,969 | 2,507 | 1.6 K to 2.5 K (+57.38 %) |
Mar 09 2015 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Payment of Exercise | F | 295.70 | 45 | 13,307 | 1,593 | 1.6 K to 1.6 K (-2.75 %) |
Mar 09 2015 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Grant | A | 0.00 | 456 | 0 | 1,638 | 1.2 K to 1.6 K (+38.58 %) |
Mar 09 2015 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Payment of Exercise | F | 295.70 | 33 | 9,758 | 1,182 | 1.2 K to 1.2 K (-2.72 %) |
Mar 06 2015 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Option Exercise | A | 296.14 | 1,169 | 346,188 | 1,169 | |
Mar 06 2015 | AGN | Allergan plc | DArecca James | CHIEF ACCOUNTING OF ... | Grant | A | 296.14 | 877 | 259,715 | 1,215 | 338 to 1.2 K (+259.47 %) |
Page: 1